Gelonghui February 25 — Baiben Medical and Healthcare (02293.HK) announced its interim results for the six months ending December 31, 2025. Revenue for the six months ended December 31, 2025, was approximately HKD 34.9 million, a decrease of about 11.6% compared to approximately HKD 39.5 million recorded for the six months ended December 31, 2024.
The profit before tax for the six months ended December 31, 2025, was approximately HKD 10.6 million, a decrease of about 17.8% compared to approximately HKD 12.9 million for the six months ended December 31, 2024.
The profit attributable to owners of the company for the six months ended December 31, 2025, was approximately HKD 9.3 million, a decrease of about 7.9% compared to approximately HKD 10.1 million for the six months ended December 31, 2024.
On February 25, 2026, the board of directors resolved not to declare an interim dividend for the six months ended December 31, 2025 (December 31, 2024: HKD 0.025 per ordinary share).
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Bai Ben Medical (02293.HK) Mid-term net profit approximately HKD 9.3 million, down about 7.9% year-on-year
Gelonghui February 25 — Baiben Medical and Healthcare (02293.HK) announced its interim results for the six months ending December 31, 2025. Revenue for the six months ended December 31, 2025, was approximately HKD 34.9 million, a decrease of about 11.6% compared to approximately HKD 39.5 million recorded for the six months ended December 31, 2024.
The profit before tax for the six months ended December 31, 2025, was approximately HKD 10.6 million, a decrease of about 17.8% compared to approximately HKD 12.9 million for the six months ended December 31, 2024.
The profit attributable to owners of the company for the six months ended December 31, 2025, was approximately HKD 9.3 million, a decrease of about 7.9% compared to approximately HKD 10.1 million for the six months ended December 31, 2024.
On February 25, 2026, the board of directors resolved not to declare an interim dividend for the six months ended December 31, 2025 (December 31, 2024: HKD 0.025 per ordinary share).